Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has active moderate to severe atopic dermatitis (AD) defined by Eczema Area and Severity Index (EASI) ≥ 16, Investigator's Global Assessment (IGA) ≥ 3, ≥ 10% body surface area (BSA) of AD involvement at the Screening and Baseline Visits, and Baseline weekly average of daily Worst Pruritus NRS ≥ 4.~* Participant is a candidate for systemic therapy or have recently required systemic therapy for AD.~Exclusion Criteria:~* Participant has prior exposure to Janus Kinase (JAK) inhibitor.~* Participant has prior exposure to dupilumab.~* Participant is unable or unwilling to discontinue current AD treatments prior to the study.~* Participant has requirement of prohibited medications during the study.~* Participant has other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of AD lesions.~* Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Upadacitinib 30 mg QD (Type: EXPERIMENTAL): Participants will receive 30 mg upadacitinib orally once a day (QD) up to Week 24 and placebo to dupilumab by subcutaneous injection every other week from Baseline to Week 22.
- Dupilumab 300 mg EOW (Type: EXPERIMENTAL): Participants will receive a loading dose of 600 mg dupilumab by subcutaneous (SC) injection on Day 1 followed by 300 mg dupilumab SC every other week (EOW) until Week 22 and placebo to upadacitinib orally QD up to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).